API Stories
Driving Inclusion in Innovation: API Recognized as an I.D.E.A.L Bioscience Employer TM
We’re excited to share that API has been recognized as an I.D.E.A.L Bioscience Employer TM for 2024-2025 by BioTalent Canada!
This recognition highlights our efforts to implement inclusion, diversity, equity and accessibility (IDEA) best practices in our workplace, helping shape a stronger Canadian bio-economy.
“API is honoured to be named an I.D.E.A.L Bioscience Employer. This recognition validates our appeal as a desirable workplace. At API, we pride ourselves on working smart and hard, while caring deeply about our mission and our colleagues. Though we each bring unique strengths, together we strive for collaboration, humility, and drive.” – Amy Gaucher, VP, Shared Services
BioTalent Canada awards this distinction to life sciences organizations across Canada that lead the way in fostering a diverse and inclusive environment, essential for driving growth and innovation. We’re proud to be among the 16 recipients of the distinction this year, including:
Thank you BioTalent Canada, for this recognition and congratulations to all the recipients! We look forward to continuing these efforts and further driving innovation and growth in the sector.
Unlocking Potential, Progress and Partnerships at OBIO
Last week, Truong Ta, our VP of Commercialization & Partnerships and Corinne Campanella, VP of Quantitative Solutions, joined industry leaders, top investors and life sciences companies from across Canada at the OBIO® Investment Summit in Toronto. They explored the future of the life sciences sector and fostered new potential partnerships and collaborations.
Our team had the opportunity to attend dynamic showcases and presentations, while engaging with a wide range of biotech, medical technology, and digital health companies.
Kudos to the OBIO team for organizing such a successful summit! We returned inspired by the groundbreaking innovations shaping the industry, and we look forward to fostering these collaborations as we continue to push boundaries and drive innovation in life sciences!
Exploring Canada’s Newest Biomanufacturing Training Facility
Last month, our team was thrilled to attend the open house for the Canadian Alliance for Skills and Training’s (CASTL) newest Biomanufacturing Training Facility in British Columbia. We toured its modern space, designed to develop and strengthen Canada’s skilled biomanufacturing workforce.
The facility features classrooms and laboratories equipped with cutting-edge tools that replicate processes and methods used to produce viral vectors, monoclonal antibodies, and other GMP biopharmaceutical products. Created to meet the growing demand for skilled biomanufacturing professionals, the facility will play a crucial role in building a robust talent pipeline by providing access to advanced resources, hands-on training and professional skills development.
Congratulations to CASTL on achieving this milestone! We’re excited to see the impact it will have on the Canadian biomanufacturing workforce!
Events
HaloHealth 26th Hybrid Investment Event
Calling all investors, healthcare professionals, industry leaders, and innovation enthusiasts! Join HaloHealth for their 26th Hybrid Investment Event on February 26 at The University Club of Toronto or online via Zoom.
This exclusive event offers an opportunity to witness groundbreaking pitches and meet the founders of HaloHealth selected ventures. Be the first to connect, collaborate, and explore high-impact investment opportunities shaping the future of health innovation. Grab your tickets now!
Attend in-person Attend onlineBioAlberta Annual Policy Forum 2025
Mark your calendars for BioAlberta’s Annual Policy Forum on February 27 and join meaningful conversations shaping Alberta’s life sciences sector!
Hear from the Honourable Adrianna LaGrange, Alberta’s Minister of Health, as she shares insights on Alberta’s health policies, government priorities, and how the province is driving innovation in the life sciences sector. The forum will also showcase dynamic panel discussions on key life sciences topics, including:
- Radiology and Diagnostics
- Alberta’s Leadership in Antimicrobial Resistance (AMR)
- Federal-Provincial Collaboration vs. Health Innovation
We’re proud to sponsor this event and support efforts that foster important dialogues critical to driving innovation in the sector. Don’t miss the chance to be part of these transformative conversations—register now!
Secure my spotLife Sciences & Innovation News
- BlueBell Village announced it received support from the UCeed Investment Funds-Cenovus Energy Equity, Diversity, and Inclusion Accelerator to advance its mission of providing personalized dementia support for caregivers.
- Entos Pharmaceuticals will receive US$4 million from the California Institute for Regenerative Medicine to advance its treatment for congenital generalized lipodystrophy.
- Nimble Science has partnered with Cmbio, which now integrates data from Nimble’s SIMBA capsule into advanced multi-omics platforms. The collaboration aims to advance understanding of microbiota-driven mechanisms affecting health, offering potential advancements in pharmaceutical, and dietary interventions.
- Northern RNA has signed a memorandum of understanding with Alexander Chemical L.P., a majority First Nations- and Canadian-owned company, to explore new opportunities that strengthen Canada’s life sciences and pharmaceuticals sectors.
- Nate Glubish, Alberta’s minister of technology and innovation, posted about a “banner year” in the province’s medical devices industry. Glubish noted PulseMedica‘s $12-million Series A funding round.
- Researchers from the University of Calgary have developed the world’s first quantum optical microscope, which uses entangled photons to provide high-resolution images without damaging cells, revolutionizing biomedical imaging and materials science. This innovative technology, now in the prototyping stage, is being commercialized by the Calgary startup QuantaSense, offering a cost-effective, powerful solution for labs, hospitals, and businesses.
- A University of Calgary startup, Rapid Infection Diagnostics, has developed a revolutionary technology called BSIDx that drastically reduces the time needed to diagnose bloodstream infections and determine effective antibiotics, cutting the process from more than 30 hours to just five. Supported by Genome Canada and PrairiesCan, the technology is currently undergoing preclinical evaluation in Alberta.
- RetinaLogik has secured $1.1 million in convertible note financing and a Class II medical device licence from Health Canada for its portable eye test product, enabling it to expand operations across North America. With this regulatory approval, RetinaLogik plans to enhance its platform, which utilizes VR and AI to provide efficient, cost-effective eye exams, and increase its presence in eye care clinics in Canada and the US. This funding round brings RetinaLogik’s total dilutive financing to more than $2 million, with additional support from both existing and new investors.